Rules-Based Medicine (RBM), a multiplexed biomarker testing laboratory, launched CardiovascularMAP, a research tool designed specifically to advance drug development aimed at the treatment of cardiovascular disease (CVD.) Designed in collaboration with leading pharmaceutical and biotechnology research groups, the 50-biomarker panel combines biomarkers most commonly associated with CVD progression with additional markers to identify new patterns of disease, resulting in a potentially powerful new tool for researchers.
CardiovascularMAP is based on RBM’s proprietary Multi-Analyte Profiling (MAP) platform, which quantifies key blood-based biomarkers representing dozens of important biological pathways. The multiplexing process allows for an optimized panel intended to heighten efficiency while providing high levels of accuracy and precision.
“As researchers gain appreciation for the critical role inflammation plays in cardiovascular and other diseases, it is important to combine known CVD biomarkers with those that report on multiple associated pathways,” said Craig Benson, RBM president and chief executive officer. “Our multiplexed panel for cardiovascular disease provides researchers with a cost-effective tool to measure established CVD biomarkers while also identifying new biomarker patterns for further exploration.”